Gastrointestinal diseases and their impact on drug solubility: Ulcerative Colitis

Simple item page
dc.contributor.authorEffinger, Angela
dc.contributor.authorO'Driscoll, Caitriona M.
dc.contributor.authorMcAllister, Mark
dc.contributor.authorFotaki, Nikoletta
dc.contributor.funderHorizon 2020en
dc.date.accessioned2022-02-16T09:37:15Z
dc.date.available2022-02-16T09:37:15Z
dc.date.issued2020-07-11
dc.date.updated2022-02-16T09:29:05Z
dc.description.abstractFor poorly soluble compounds, drug product performance in patients with Ulcerative Colitis (UC) compared to healthy subjects can be affected due to differences in drug solubility in GI fluids. A risk assessment tool was developed to identify compounds with a high risk of altered solubility in the GI fluids of UC patients. Pathophysiological changes impacting on the composition of GI fluids in UC patients were considered and UC biorelevant media representative of the stomach, intestine and colon were developed based on biorelevant media based on healthy subjects and literature data using a Design of Experiment approach. The UC media were characterised and revealed differences in surface tension, osmolality and buffer capacity compared to media based on healthy subjects. The solubility of six drugs was investigated in UC biorelevant media and results were related to media- and drug-dependent factors. A lower drug solubility in UC intestinal media was observed for compounds with a high lipophilicity. In UC simulated colonic fluids, drug solubility was altered for ionisable compounds. Additionally, a higher solubility of neutral lipophilic drugs was observed in UC fasted state colonic media with increased concentrations of soluble proteins. The developed UC biorelevant media offer the possibility to identify the risk of altered drug solubilisation in UC patients without conducting expensive clinical trials. A high risk was related to drug ionization properties and lipophilicity in the current study with all investigated drugs showing differences in solubility in biorelevant media based on UC patients compared to healthy subjects.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid105458en
dc.identifier.citationEffinger, A., O'Driscoll, C. M., McAllister, M. and Fotaki, N. (2020) 'Gastrointestinal diseases and their impact on drug solubility: Ulcerative Colitis', European Journal of Pharmaceutical Sciences, 152, 105458 (12pp). doi: 10.1016/j.ejps.2020.105458en
dc.identifier.doi10.1016/j.ejps.2020.105458en
dc.identifier.eissn1520-6017
dc.identifier.endpage12en
dc.identifier.issn0928-0987
dc.identifier.journaltitleEuropean Journal of Pharmaceutical Sciencesen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/12571
dc.identifier.volume152en
dc.language.isoenen
dc.publisherElsevier B.V.en
dc.relation.projectinfo:eu-repo/grantAgreement/EC/H2020::MSCA-ITN-ETN/674909/EU/Pharmaceutical Education And Research with Regulatory Links: Innovative drug development strategies and regulatory tools tailored to facilitate earlier access to medicines/PEARRLen
dc.rights© 2020, Elsevier B.V. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectBiorelevant mediaen
dc.subjectGastrointestinal diseasesen
dc.subjectInflammatory Bowel Diseaseen
dc.subjectPhysicochemical propertiesen
dc.subjectSolubilityen
dc.subjectUlcerative Colitisen
dc.titleGastrointestinal diseases and their impact on drug solubility: Ulcerative Colitisen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13421_Ulcerative.pdf
Size:
1.68 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacy - Journal Articles